Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Pulmonary disease

Pulmonary fibrosis

NADPH oxidase 4 (NOX4)

Mouse studies suggest inhibiting NOX4 could help treat age-related lung fibrosis. In aged mice with chemically induced pulmonary fibrosis, siRNA against Nox4 or pharmacological inhibition with the small molecule GKT137831 increased fibrosis resolution and the recovery of body weight compared with control siRNA or no inhibition. Next steps include conducting further studies of GKT137831 and identifying additional NOX4 inhibitors to treat fibrosis.
Genkyotex S.A.'s dual NOX1 and NOX4 inhibitor, GKT137831, is in Phase II testing to treat diabetic nephropathy and preclinical development for liver and pulmonary fibrosis.

SciBX 7(18); doi:10.1038/scibx.2014.533
Published online May 8, 2014

Unpatented; licensing status not applicable

Hecker, L. et al. Sci. Transl. Med.; published online April 9, 2014;
doi:10.1126/scitranslmed.3008182
Contact: Victor J. Thannickal, The University of Alabama at Birmingham, Birmingham, Ala.
e-mail:

vjthan@uab.edu
Contact: Louise Hecker, same affiliation as above
e-mail:

lhecker@uab.edu